- Home
- RGNX vs NIE Comparison
RGNX vs NIE Comparison
Compare RGNX & NIE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RGNX | NIE |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 793.5M | 726.3M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | RGNX | NIE |
|---|---|---|
| Price | $7.45 | $25.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $28.75 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 69.2K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.04% |
| EPS Growth | ★ 18.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,393,000.00 | N/A |
| Revenue This Year | $51.21 | N/A |
| Revenue Next Year | $19.08 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 126.48 | N/A |
| 52 Week Low | $5.46 | $22.78 |
| 52 Week High | $16.19 | $27.24 |
Technical Indicators
Market Signals| Indicator | RGNX | NIE |
|---|---|---|
| Relative Strength Index (RSI) | 34.34 | 38.14 |
| Support Level | $5.67 | $24.77 |
| Resistance Level | $11.43 | $25.66 |
| Average True Range (ATR) | 0.45 | 0.45 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 12.07 | 17.83 |
Price Performance
Historical ComparisonAbout RGNX REGENXBIO Inc.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
About NIE Virtus Equity & Convertible Income Fund of Beneficial Interest
Virtus AllianzGI Equity & Convertible Income Fund is a diversified, closed-end management investment company. The investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. The fund pursues its objective by investing in a diversified portfolio of equity securities and income-producing convertible securities. Its portfolio of investments comprises different sector investments, such as aerospace and defense, banks, IT services, software, and others.